Aller au contenu principal
Profil bibliographique

John M. Storring

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

55Publications signalées
1526Citations signalées
3Affiliations récentes

Les institutions déclarées

Les domaines associés

Acute Myeloid Leukemia ResearchHemoglobinopathies and Related DisordersAcute Lymphoblastic Leukemia researchHematopoietic Stem Cell TransplantationChronic Myeloid Leukemia Treatments

Les publications récentes

2025 conference-abstract OpenAlex

A comparison of overall survival and quality of life in MDS patients treated with azacytidine vs decitabine: A propensity matched registry Study

James T. England, Michelle Geddes, Mitchell Sabloff, Grace Christou et autres

Abstract Background Myelodysplastic neoplasms (MDS) are a group of clonal malignancies of hematopoietic stem cells where progressive cytopenias and potential progression to secondary Acute Myeloid Leukemia (AML) lead to significant morbidity/mortality, impaired quality-of-life (QoL), and healthcare resource burden. Patients with higher-risk MDS …

ca (code pays fourni par la source)

0 citations Blood
2025 conference-abstract OpenAlex

Grip strength predicts overall survival of patients with myelodysplastic syndrome in a multivariable model

Nicholas L.J. Chornenki, Lisa Chodirker, Lee Mozessohn, Signy Chow et autres

Abstract Background: Myelodysplastic syndrome (MDS) is a clonal hematologic disorder characterized by cytopenias and a risk of progression to leukemia. Frailty, a state of reduced physiologic reserve, is prevalent among older individuals and is common in patients with MDS. MDS specific frailty …

ca (code pays fourni par la source)

0 citations Blood
Accès ouvert 2025 article OpenAlex

Leaky Artemis Deficiency and EBV‐Related Lymphoproliferative Disease: A Novel Case and Review of the Literature

Lucie Roussel, Stephane Bernier, Gertruda Evaristo, Anna Pérez et autres

Introduction: ) deficiency causes radiosensitive severe combined immunodeficiency (SCID), although hypomorphic cases can manifest later-onset immunodeficiency, autoimmunity, or lymphoproliferation. We report a 45-year-old man with humoral immunodeficiency, opportunistic infections, and recurrent EBV-positive diffuse large B-cell lymphoma (DLBCL). Methods: gene. Functional studies, including …

ca (code pays fourni par la source)

0 citations eJHaem
2024 article OpenAlex

Improvement in quality of life in MDS patients who become transfusion independent after treatment

Betty Wan, Shabbir M.H. Alibhai, Lisa Chodirker, Lee Mozessohn et autres

Myelodysplastic syndromes (MDSs) treatment focuses on improving quality of life (QOL), affected by anemia and transfusion dependence (TD). Using the MDS-CAN registry, we studied how changes in transfusion status – TD to transfusion independence (TI) (group A), or vice versa (group B), …

ca (code pays fourni par la source)

2 citations Leukemia & lymphoma/Leukemia and lymphoma
2024 conference-abstract OpenAlex

Improvement in Quality of Life in MDS Patients Who Become Transfusion Independent after Treatment

Bo Wan, S. M. H. Alibhai, Lisa Chodirker, Lee Mozessohn et autres

Introduction: Patients with myelodysplastic syndromes (MDS) generally experience inferior quality of life (QOL), in part due to transfusion dependent-anemia and. Many studies have shown that patients who are transfusion dependent (TD) typically have worse QOL compared to patients who are transfusion independent …

ca (code pays fourni par la source)

1 citation Blood
2024 conference-abstract OpenAlex

Gemtuzumab Ozogamicin in Favorable and Intermediate Risk Acute Myeloid Leukemia: A Single-Center Experience

Jia Li Liu, Nushin Sadeghi, Owen Dan Luo, Jonathan How et autres

Background Acute Myeloid Leukemia (AML) is a common form of leukemia in adults. Gemtuzumab Ozogamicin (GO), an anti-CD33 antibody linked to a chemotherapy molecule, demonstrated improved event-free survival (EFS) and overall survival (OS) in favorable and intermediate risk AML when given with …

ca (code pays fourni par la source)

0 citations Blood
Accès ouvert 2024 conference-abstract OpenAlex

Age ≥60 Is an Added Risk Factor for Mortality in High-Risk HCT-CI Patients Undergoing Allogeneic Stem Cell Transplant

Veronica Ramirez, Gizelle Popradi, John M. Storring, Jonathan How

Introduction: Allogeneic hematopoietic stem cell transplant (HCT) is the only curative option for many hematologic malignancies, yet non-relapse mortality (NRM) remains a challenge. Since its development in 2003, the HCT Comorbidity Index (HCT-CI) has been widely adopted to estimate NRM and overall …

ca (code pays fourni par la source)

0 citations Blood
2024 conference-abstract OpenAlex

Impact of Frailty in a Prospective Cohort of Patients with MDS Treated with Hypomethylating Agents

James T. England, Liying Zhang, Karen Yee, Michelle Geddes et autres

Introduction: Myelodysplastic neoplasms (MDS) are a group of clonal hematopoietic disorders characterized by cytopenias and a risk of progression to Acute Myeloid Leukemia. Frailty is an age-related state of vulnerability that reflects multifactorial loss of physiologic reserve. Up to 25% of patients …

ca (code pays fourni par la source)

1 citation Blood
2024 article OpenAlex

Evaluating the Economic Burden of Acute Myeloid Leukemia in Canada

Jean Lachaîne, C. Beauchemin, Fatéma Dodat, Yunghan Au et autres

INTRODUCTION: Acute myeloid leukemia (AML) represents a significant burden for patients and their families, and to the healthcare system. This study estimated the total cost of illness associated with newly diagnosed AML patients in Canada. METHODS: The economic burden of AML was …

kr, ca (code pays fourni par la source)

0 citations Acta Haematologica
Accès ouvert 2023 article OpenAlex

The burden of red blood cell transfusions in patients with lower-risk myelodysplastic syndromes and ring sideroblasts: an analysis of the prospective MDS-CAN registry

Rena Buckstein, Lisa Chodirker, Karen Yee, Michelle Geddes et autres

Many patients with lower-risk myelodysplastic syndromes (LR MDS) require long-term red blood cell (RBC) transfusions to manage anemia. The consequences of RBC transfusions in LR MDS with ring sideroblasts (LR MDS-RS) are not well known. We estimated the association between cumulative RBC …

ca, us (code pays fourni par la source)

13 citations Leukemia & lymphoma/Leukemia and lymphoma
Accès ouvert 2022 article OpenAlex

A natural history of lower-risk myelodysplastic syndromes with ring sideroblasts: an analysis of the MDS-CAN registry

Rena Buckstein, Lisa Chodirker, Lee Mozessohn, Karen Yee et autres

Patients with lower-risk (LR) myelodysplastic syndromes (MDS) with ring sideroblasts (RS) have better prognosis than those without RS, but how they fare over time is not fully understood. This study’s objective was to assess the natural history of LR MDS with RS …

ca, us (code pays fourni par la source)

6 citations Leukemia & lymphoma/Leukemia and lymphoma
Accès ouvert 2022 article OpenAlex

High transferrin saturation predicts inferior clinical outcomes in patients with myelodysplastic syndromes

Jennifer Teichman, Michelle Geddes, Nancy Zhu, Mary‐Margaret Keating et autres

Iron overload (IO) reflected by elevated ferritin is associated with increased mortality in myelodysplastic syndromes (MDS), however, ferritin is an imperfect metric. Elevated labile plasma iron correlates with clinical outcomes and transferrin saturation (TSAT) >80%, but is not readily measurable. The trajectory …

ca (code pays fourni par la source)

14 citations Haematologica

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.